ArticleBMC cancer2023

Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study.

Neehar D Parikh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.